Background Clinical guidelines optimize care delivery and outcomes. Guidelines support
patient engagement and adherence if they reflect patient preferences for treatment options …

Objectives Organisations that develop clinical practice guidelines (CPGs) encourage
involvement of patients and the publics in their development, however, there are no …

Background Arginine vasopressin promotes kidney cyst growth in autosomal dominant
polycystic kidney disease (ADPKD). Increased water intake reduces arginine vasopressin …

Introduction Maintaining fluid intake sufficient to reduce arginine vasopressin (AVP)
secretion has been hypothesised to slow kidney cyst growth in autosomal dominant …

Background Guidelines based on patient preferences differ from those developed solely by
clinicians and may promote patient adherence to guideline recommendations. There is …

Objectives The involvement of consumers (people with lived experience of disease) in
guidelines is widely advocated to improve their relevance and uptake. However, the …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic
nephropathy, and tolvaptan is the only therapy available. However, tolvaptan slows but does …

Rationale & Objective Outcomes reported in trials involving patients with autosomal
dominant polycystic kidney disease (ADPKD) are heterogeneous and rarely include patient …

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition
characterized by the development and growth of cysts in the kidneys and other organs and …

Achieving parenthood is often a priority and goal for women with chronic kidney disease
(CKD). It can be challenging due to medical and emotional complexities around pregnancy …